Both treatment approaches resulted in a mean weight loss at 52 weeks, with oral semaglutide treatment resulting in a mean weight loss from baseline of 3.8 kg and 4.7 kg in the treatment-policy estimand and trial-product estimand analyses, respectively
These include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
Consequently, loss of FMRP results in an aberrantly increased mGluRI expression in these neurons, leading to enhanced mGluR-related long-term depression causing cognitive impairments and intellectual disability
Side effects are generally mild and short-lived
Studies have found that the longer cellular damage is allowed to occur, the more cellular function is impaired, giving way to the accumulation of even more damaged cells and accelerated aging